MultiCell announces new cancer therapeutics preclinical results
MCT-465 and MCT-485 are cancer therapeutics, which use TLR3 signaling technology. During the trials, MCT-485 showed in vitro dose-effect cytotoxicity on several human hepatocellular carcinoma cell lines while
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.